Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center

Cameron Trodello, Shauna Higgins, Omeed Ahadiat, Omar Ragab, Gino In, Makenzie Hawkins, Ashley Wysong

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and has potential for regional or distant metastasis. Despite the standardization of features associated with high-risk cSCC, an advanced subset of cSCC, there is no established consensus regarding proper management of this tumor.OBJECTIVETo evaluate the efficacy of cetuximab, add to existing management options, and aid in the development of standardized treatment for this tumor.MATERIALS AND METHODSMedical records were searched using Current Procedural Terminology codes for cetuximab and cSCC. Demographic data and tumor characteristics, along with treatment regimens and follow-up times, were collected. A total of 20 cases were examined.RESULTSOf the 20 cases, 3 experienced a complete response and 7 experienced a partial response, yielding an overall response of 50% and a combined median disease-free survival of 6.35 months (range 1-46.8 months).CONCLUSIONAs most of the patients who experienced a response received cetuximab as part of a multimodality treatment approach, cetuximab may be most efficacious when administered with concurrent therapies such as surgery or radiation. Further larger prospective studies to determine the optimal dosing and frequency of cetuximab and the utility of concurrent therapies are warranted.

Original languageEnglish (US)
Pages (from-to)254-267
Number of pages14
JournalDermatologic Surgery
Volume45
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Squamous Cell Carcinoma
Skin
Current Procedural Terminology
Therapeutics
Neoplasms
Skin Neoplasms
Disease-Free Survival
Demography
Cetuximab
Prospective Studies
Radiation
Neoplasm Metastasis

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma : A Retrospective Analysis From a Single Tertiary Academic Medical Center. / Trodello, Cameron; Higgins, Shauna; Ahadiat, Omeed; Ragab, Omar; In, Gino; Hawkins, Makenzie; Wysong, Ashley.

In: Dermatologic Surgery, Vol. 45, No. 2, 01.02.2019, p. 254-267.

Research output: Contribution to journalArticle

Trodello, Cameron ; Higgins, Shauna ; Ahadiat, Omeed ; Ragab, Omar ; In, Gino ; Hawkins, Makenzie ; Wysong, Ashley. / Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma : A Retrospective Analysis From a Single Tertiary Academic Medical Center. In: Dermatologic Surgery. 2019 ; Vol. 45, No. 2. pp. 254-267.
@article{fc161e64fbae4736a0030a6683742647,
title = "Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center",
abstract = "BACKGROUND Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and has potential for regional or distant metastasis. Despite the standardization of features associated with high-risk cSCC, an advanced subset of cSCC, there is no established consensus regarding proper management of this tumor.OBJECTIVETo evaluate the efficacy of cetuximab, add to existing management options, and aid in the development of standardized treatment for this tumor.MATERIALS AND METHODSMedical records were searched using Current Procedural Terminology codes for cetuximab and cSCC. Demographic data and tumor characteristics, along with treatment regimens and follow-up times, were collected. A total of 20 cases were examined.RESULTSOf the 20 cases, 3 experienced a complete response and 7 experienced a partial response, yielding an overall response of 50{\%} and a combined median disease-free survival of 6.35 months (range 1-46.8 months).CONCLUSIONAs most of the patients who experienced a response received cetuximab as part of a multimodality treatment approach, cetuximab may be most efficacious when administered with concurrent therapies such as surgery or radiation. Further larger prospective studies to determine the optimal dosing and frequency of cetuximab and the utility of concurrent therapies are warranted.",
author = "Cameron Trodello and Shauna Higgins and Omeed Ahadiat and Omar Ragab and Gino In and Makenzie Hawkins and Ashley Wysong",
year = "2019",
month = "2",
day = "1",
doi = "10.1097/DSS.0000000000001755",
language = "English (US)",
volume = "45",
pages = "254--267",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma

T2 - A Retrospective Analysis From a Single Tertiary Academic Medical Center

AU - Trodello, Cameron

AU - Higgins, Shauna

AU - Ahadiat, Omeed

AU - Ragab, Omar

AU - In, Gino

AU - Hawkins, Makenzie

AU - Wysong, Ashley

PY - 2019/2/1

Y1 - 2019/2/1

N2 - BACKGROUND Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and has potential for regional or distant metastasis. Despite the standardization of features associated with high-risk cSCC, an advanced subset of cSCC, there is no established consensus regarding proper management of this tumor.OBJECTIVETo evaluate the efficacy of cetuximab, add to existing management options, and aid in the development of standardized treatment for this tumor.MATERIALS AND METHODSMedical records were searched using Current Procedural Terminology codes for cetuximab and cSCC. Demographic data and tumor characteristics, along with treatment regimens and follow-up times, were collected. A total of 20 cases were examined.RESULTSOf the 20 cases, 3 experienced a complete response and 7 experienced a partial response, yielding an overall response of 50% and a combined median disease-free survival of 6.35 months (range 1-46.8 months).CONCLUSIONAs most of the patients who experienced a response received cetuximab as part of a multimodality treatment approach, cetuximab may be most efficacious when administered with concurrent therapies such as surgery or radiation. Further larger prospective studies to determine the optimal dosing and frequency of cetuximab and the utility of concurrent therapies are warranted.

AB - BACKGROUND Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and has potential for regional or distant metastasis. Despite the standardization of features associated with high-risk cSCC, an advanced subset of cSCC, there is no established consensus regarding proper management of this tumor.OBJECTIVETo evaluate the efficacy of cetuximab, add to existing management options, and aid in the development of standardized treatment for this tumor.MATERIALS AND METHODSMedical records were searched using Current Procedural Terminology codes for cetuximab and cSCC. Demographic data and tumor characteristics, along with treatment regimens and follow-up times, were collected. A total of 20 cases were examined.RESULTSOf the 20 cases, 3 experienced a complete response and 7 experienced a partial response, yielding an overall response of 50% and a combined median disease-free survival of 6.35 months (range 1-46.8 months).CONCLUSIONAs most of the patients who experienced a response received cetuximab as part of a multimodality treatment approach, cetuximab may be most efficacious when administered with concurrent therapies such as surgery or radiation. Further larger prospective studies to determine the optimal dosing and frequency of cetuximab and the utility of concurrent therapies are warranted.

UR - http://www.scopus.com/inward/record.url?scp=85061134240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061134240&partnerID=8YFLogxK

U2 - 10.1097/DSS.0000000000001755

DO - 10.1097/DSS.0000000000001755

M3 - Article

C2 - 30672860

AN - SCOPUS:85061134240

VL - 45

SP - 254

EP - 267

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 2

ER -